ZEPBOUND VS MOUNJARO: WHAT YOU NEED TO KNOW 

In recent years, the medical world has witnessed remarkable progress in the fight against obesity and type 2 diabetes. Two of the most talked-about treatments are Zepbound and Mounjaro. At first glance, they may seem almost identical—both contain the same active ingredient, tirzepatide—but their indications, uses, and outcomes differ in important ways. 

At Reem Hospital, our mission is to provide patients with clear, evidence-based knowledge so they can make informed health decisions.  

In this blog, we’ll explore how Zepbound and Mounjaro compare, who qualifies for them, and what patients should know about side effects, BMI requirements, and special considerations like pregnancy. 

Zepbound vs Mounjaro

Both Zepbound and Mounjaro ‘s active ingredient is tirzepatide, a medication that activates two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism helps regulate blood sugar, reduce appetite, and promote weight loss. 

• Mounjaro is approved for type 2 diabetes management, helping patients improve blood sugar control alongside diet and exercise. 

• Zepbound is approved for chronic weight management in adults with obesity or overweight and, more recently, for obstructive sleep apnea (OSA) in adults with obesity. 

In short, Mounjaro is labeled for diabetes, while Zepbound is labeled for obesity and related conditions. 

How Tirzepatide Works 

Tirzepatide is often called a “dual-action” medicine because it works on two natural hormones in your body that control blood sugar and appetite. This makes it especially powerful. Here’s how it helps: 

• Helps your body release more insulin when blood sugar levels are high. 

• Stops the liver from making too much sugar, keeping blood sugar steady. 

• Slows down digestion, so you feel fuller for longer after meals. 

• Tells your brain you’re less hungry, which helps cut cravings. 

By working in these ways, tirzepatide not only helps with weight loss but also supports better overall metabolism and health. 

BMI Requirements for Zepbound 

Zepbound eligibility is based on Body Mass Index (BMI): 

• BMI ≥30 (obesity): Eligible regardless of other conditions. 

• BMI ≥27 (overweight) + health condition: Such as hypertension, diabetes, or high cholesterol. 

• OSA Patients with obesity: Eligible even without additional conditions. 

At Reem Hospital, we use BMI as a guideline but also assess overall health, lifestyle, and medical history to create personalized treatment plans. 

Effectiveness

• Weight Loss: In Surmount-1 clinical trials, patients lost up to 20–22% of body weight on tirzepatide after 72 weeks. 

• Blood sugar control (Mounjaro). 

• Sleep Apnea (Zepbound): Significant reductions in apnea events, mainly due to weight loss. 

Dosing & Administration 

Both Zepbound and Mounjaro are both:

• Taken as a weekly subcutaneous injection under the skin (thigh, abdomen, or upper arm). 
• Starting dose is 2.5 mg once a week, increased gradually to improve tolerance 
• Maximum dose 15 mg weekly (based on doctor’s recommendations) 
• Can be taken with food or without food 
• Rotate the injection site each week. 

Side Effects and Management 

Like most GLP-1 therapies, both medications share common side effects: 

• Nausea 
• Diarrhea 
• Constipation 
• Stomach pain 
• Decreased appetite 
• Hair shedding (temporary) 

Tips to Manage Diarrhea during Zepbound

• Eat smaller, lighter meals. 
• Avoid greasy or spicy foods. 
• Stay well-hydrated. 
• Report persistent symptoms to your doctor—dose adjustments may help. 

How to Support Hair Health

• Eat a nutrient-rich diet with protein, iron, and vitamins. 
• Consider supplements if recommended by your doctor. 
• Manage stress, which can worsen shedding. 

Most of these symptoms are temporary and improve as the body adjusts. Rare but serious risks include pancreatitis and potential thyroid tumors in at-risk individuals. This underscores the importance of consulting an expert endocrinologist for your safety. 

Safety in Pregnancy and breast feeding 

Zepbound is not recommended during pregnancy. 

• Animal studies show potential risks for fetal development. 
• Women should stop either Mounjaro or Zepbound at least 12 weeks before pregnancy, as the drug remains in the system for weeks. 
• It should also be avoided during breastfeeding. 
• Discuss family planning with your endocrinologist 

At Reem Hospital, our specialists coordinate care between endocrinology and obstetrics to ensure safe family planning. 

Conclusion

Tirzepatide is marketed under two different names, each approved for distinct uses: Mounjaro is indicated for the treatment of type 2 diabetes, while Zepbound is approved for chronic weight management, including obesity-related conditions such as obstructive sleep apnea. 

At Reem Hospital, we’re here to guide you with expert care and personalized support—because your journey to better health deserves nothing less. 

More info